LifeMD, Inc. (NASDAQ:LFMD) Receives $9.14 Consensus Price Target from Brokerages

Shares of LifeMD, Inc. (NASDAQ:LFMD) have received an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $9.1429.

A number of research firms have recently weighed in on LFMD. BTIG Research reaffirmed a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research report on Monday, May 4th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of LifeMD in a research note on Tuesday, May 26th. UBS Group reiterated a “buy” rating on shares of LifeMD in a research note on Wednesday, May 27th. Wall Street Zen downgraded LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Weiss Ratings upgraded LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research note on Thursday, May 7th.

LifeMD Price Performance

Shares of LFMD stock opened at $3.71 on Monday. The company has a market cap of $179.42 million, a price-to-earnings ratio of 74.21 and a beta of 1.99. LifeMD has a 1 year low of $2.56 and a 1 year high of $12.72. The firm has a fifty day moving average price of $4.51 and a 200-day moving average price of $3.99.

LifeMD (NASDAQ:LFMD) last released its earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.06). LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. The company had revenue of $50.16 million for the quarter, compared to analysts’ expectations of $48.84 million. Equities research analysts expect that LifeMD will post -0.37 EPS for the current year.

Institutional Trading of LifeMD

A number of institutional investors and hedge funds have recently bought and sold shares of LFMD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of LifeMD by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after purchasing an additional 2,235 shares during the last quarter. Creative Planning bought a new stake in LifeMD in the second quarter worth $272,000. JPMorgan Chase & Co. raised its stake in LifeMD by 581.2% during the second quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after purchasing an additional 352,004 shares in the last quarter. Legal & General Group Plc raised its position in shares of LifeMD by 187.4% during the 2nd quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock valued at $138,000 after buying an additional 6,614 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of LifeMD by 8.7% in the 2nd quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock valued at $730,000 after acquiring an additional 4,281 shares during the last quarter. 35.52% of the stock is currently owned by institutional investors.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.